Alacris Theranostics GmbH
Dr. Bodo Lange carried out his PhD at the University of Manchester (UK) followed by postdoctoral research at the European Molecular Biology Laboratory (EMBL) Heidelberg (Germany). In 2003, he habilitated, took up a group leader position at the Max Planck Institute for molecular Genetics, and became lecturer at the Free University of Berlin, Germany. Bodo Lange was appointed CEO of Alacris Theranostics GmbH in 2011. Alacris was founded by pioneers in the fields of genomics, new generation sequencing applications and systems biology with the aim of translating research innovations into benefits for patients enabling novel approaches in precision medicine.
CanPathPro – Development of a platform for predictive cancer pathway modelling
One of the greatest challenges in cancer research is to utilize the vast and dynamic influx of “omics” data. The CanPathPro project addresses the challenge of predictive modelling of biological data by developing and refining bioinformatic and experimental tools for the creation and experimental validation of systems biology modelling predictions. Components of the project comprise highly defined mouse and organotypic experimental systems, next generation sequencing, quantitative proteomics and a systems biology computational model for data integration, visualisation and predictive modelling. CanPathPro aims to have broad impact on diverse areas of cancer research, personalised medicine and drug development, ultimately improving outcomes for cancer patients.
- Regional Session I: Biotech & Pharma on November 20, 2017 11:45 am